Cargando…
RF35 | PSAT299 Thyroid Eye Disease Activation After mRNA SARS-CoV-2 Vaccination in Patients With Autoimmune Thyroid Disease
BACKGROUND: Occurrence of Graves’ disease (GD) has been reported following SARS-CoV-2 vaccine administration, but little is known about thyroid eye disease (TED) after SARS-CoV-2 vaccination. CASE 1: A 50-year-old non-smoker male was diagnosed with GD in March 2019 and treated with methimazole. In A...
Autores principales: | Mohamed, Abubakr, Tzoulis, Ploutarchos, Kossler, Andrea Lora, Dosiou, Chrysoula |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628953/ http://dx.doi.org/10.1210/jendso/bvac150.1784 |
Ejemplares similares
-
SAT-500 Response to Tocilizumab Retreatment in Refractory Thyroid Eye Disease
por: Kaplan, Daniel, et al.
Publicado: (2020) -
RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients
por: Smith, Terry J, et al.
Publicado: (2022) -
RF35 | PSAT298 Subacute Thyroiditis Following SARS-CoV-2 mRNA Vaccine
por: Pandey, Shanta, et al.
Publicado: (2022) -
RF35 | PSAT257 The Severity of Subacute Thyroiditis Depends on Its Causative Agent
por: Brancatella, Alessandro, et al.
Publicado: (2022) -
Thyroid Eye Disease: Navigating the New Treatment Landscape
por: Dosiou, Chrysoula, et al.
Publicado: (2021)